MARKET

AFMD

AFMD

Affimed
NASDAQ
0.5509
-0.0518
-8.59%
After Hours: 0.5508 -0.0001 -0.02% 17:22 02/20 EST
OPEN
0.6100
PREV CLOSE
0.6027
HIGH
0.6100
LOW
0.5360
VOLUME
998.47K
TURNOVER
0
52 WEEK HIGH
1.110
52 WEEK LOW
0.2235
MARKET CAP
82.27M
P/E (TTM)
-0.6530
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AFMD last week (0212-0216)?
Weekly Report · 1d ago
Weekly Report: what happened at AFMD last week (0205-0209)?
Weekly Report · 02/12 12:20
Weekly Report: what happened at AFMD last week (0129-0202)?
Weekly Report · 02/05 12:33
Weekly Report: what happened at AFMD last week (0122-0126)?
Weekly Report · 01/29 12:15
Weekly Report: what happened at AFMD last week (0115-0119)?
Weekly Report · 01/22 12:22
Weekly Report: what happened at AFMD last week (0108-0112)?
Weekly Report · 01/15 12:16
Affimed: Report of foreign issuer
Press release · 01/08 22:09
Affimed Provides Clinical Response Update On AFM24-102 Trial In EGFR-Wildtype Non-Small Cell Lung Cancer
Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype lung cancer (NSCLC) expansion cohort. Three of the initially reported responses have now been confirmed. Study to be expanded to a total of 40 EGFRwt NSCLC patients. Enrollment in theEGFR-mutant (mut) cohort is ongoing. Data from both cohorts expected in H1 2024.
Benzinga · 01/08 21:16
More
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Webull offers Affimed NV stock information, including NASDAQ: AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.